Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder

Summary

The proposed study is for a 6 week open-label clinical trial in which Seroquel XR is added to a selective serotonin reuptake inhibitor (SSRI) medication for the treatment of depressive and/or anxiety symptoms. Each subject will self-report changes in symptoms, functional impairment, etc. on a twice daily basis using a handheld computer (HHC) that transmits real-time symptoms reports to a central database. Each subject will be assessed in-person on a weekly or biweekly basis during the course of the study.

Timeline

Start

2009-05

Primary completion

2010-12

Completion

2010-12

Drugs

Indications